- Home
- YGMZ vs ABVC Comparison
YGMZ vs ABVC Comparison
Compare YGMZ & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- ABVC
- Stock Information
- Founded
- YGMZ 2002
- ABVC 2015
- Country
- YGMZ China
- ABVC United States
- Employees
- YGMZ N/A
- ABVC N/A
- Industry
- YGMZ Transportation Services
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- YGMZ Consumer Discretionary
- ABVC Health Care
- Exchange
- YGMZ Nasdaq
- ABVC Nasdaq
- Market Cap
- YGMZ 7.5M
- ABVC 6.5M
- IPO Year
- YGMZ 2020
- ABVC N/A
- Fundamental
- Price
- YGMZ $1.03
- ABVC $0.50
- Analyst Decision
- YGMZ
- ABVC
- Analyst Count
- YGMZ 0
- ABVC 0
- Target Price
- YGMZ N/A
- ABVC N/A
- AVG Volume (30 Days)
- YGMZ 19.5K
- ABVC 361.8K
- Earning Date
- YGMZ 01-01-0001
- ABVC 11-14-2024
- Dividend Yield
- YGMZ N/A
- ABVC N/A
- EPS Growth
- YGMZ N/A
- ABVC N/A
- EPS
- YGMZ N/A
- ABVC N/A
- Revenue
- YGMZ $89,002,243.00
- ABVC $509,788.00
- Revenue This Year
- YGMZ N/A
- ABVC N/A
- Revenue Next Year
- YGMZ N/A
- ABVC N/A
- P/E Ratio
- YGMZ $14.50
- ABVC N/A
- Revenue Growth
- YGMZ N/A
- ABVC N/A
- 52 Week Low
- YGMZ $0.91
- ABVC $0.41
- 52 Week High
- YGMZ $6.24
- ABVC $2.45
- Technical
- Relative Strength Index (RSI)
- YGMZ 35.59
- ABVC 36.66
- Support Level
- YGMZ $1.04
- ABVC $0.47
- Resistance Level
- YGMZ $1.25
- ABVC $0.52
- Average True Range (ATR)
- YGMZ 0.09
- ABVC 0.04
- MACD
- YGMZ 0.00
- ABVC -0.00
- Stochastic Oscillator
- YGMZ 8.33
- ABVC 25.56
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. Its segments are the trucking business, car owner services business, and liquor distribution business. It generates the majority of its revenue from the trucking segment.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.